Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab, Docetaxel, and ADT in Metastatic Hormone Sensitive Prostate Cancer
NCT04126070Phase 2Active, not recruiting
- Start
- May 2020
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab in prostate cancer (PCa) (3 cohorts). Primary endpoint: Percentage of Subjects With Prostate Specific Antigen (PSA) Less Than or Equal to 0.2 ng/mL at 7 months. Started May 2020; status: active, not recruiting.
02
Drugs
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04126070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04126070.